SCHEMBL163795

SCHEMBL163795

OCc1ccc(-c2n[nH]c3cccc(Cc4ccccc4)c23)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.44
EPAS1 Q99814 4/20 0.44
PDE5A O76074 6/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
GMNN O75496 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8470062 0.91 CYP1A2 (0.36) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL8330242 0.90 MAP2K4 (0.39) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL8470284 0.88 CYP2D6 (0.41) HIF1AEPAS1CYP1A2CYP3A4CYP2D6
SCHEMBL8328669 0.88 MAP2K4 (0.43) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL8332364 0.86 PDE5A (0.41) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL5971777 0.85 PDE5A (0.45) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL8329920 0.85 PDE5A (0.44) HIF1AEPAS1PDE5ASMN1; SMN2MAP2K4
SCHEMBL8471597 0.83 MAP2K1 (0.41) HIF1AEPAS1PDE5ACYP1A2CYP3A4
SCHEMBL8329288 0.83 PDE5A (0.40) PDE5ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8470520 0.81 CYP1A2 (0.39) HIF1ACYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012152295-A1 PYRAZOLYL COMPOUNDS FOR USE IN REVERSING REACTIVE GLIOSIS KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) 2012-11-15 WO claimed
WO-2012154975-A2 NITRIC OXIDE/CGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION STC.UNM (US) 2012-11-15 WO claimed
EP-2161977-A1 USE OF ABSCISIC ACID SEED TREATMENT TO ENHANCE CORN EMERGENCE AFTER EARLY PLANTING Valent Biosciences Corporation (US) 2010-03-17 EP claimed
EP-2154956-A2 SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES Bayer Schering Pharma AG (DE) 2010-02-24 EP claimed
WO-2008156859-A1 USE OF ABSCISIC ACID SEED TREATMENT TO ENHANCE CORN EMERGENCE AFTER EARLY PLANTING VALENT BIOSCIENCES CORPORATION (US) 2008-12-24 WO claimed
WO-2008148474-A2 SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-11 WO claimed
WO-2006081327-A2 SMALL MOLECULES THAT REDUCE FUNGAL GROWTH UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2006-08-03 WO claimed
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP claimed
WO-2005077005-A2 ENHANCING THE EFFECTIVENESS OF AN INHALED THERAPEUTIC GAS THE GENERAL HOSPITAL CORPORATION (US) 2005-08-25 WO claimed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO claimed
WO-2004091648-A1 METHOD FOR INHIBITING TUMOR ANGIOGENESIS AND TUMOR GROWTH HIF BIO INC. (US) 2004-10-28 WO claimed
EP-1220945-A2 SCREEN FOR AXON VIABILITY UNIVERSITY COLLEGE LONDON (GB) 2002-07-10 EP claimed
WO-2001016359-A2 SCREEN FOR AXON VIABILITY UNIVERSITY COLLEGE LONDON (GB) 2001-03-08 WO claimed
EP-3108245-B1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL HENKIN ROBERT I (US) 2020-07-22 EP disclosed
EP-3484894-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS Bristol-Myers Squibb Company (US) 2019-05-22 EP disclosed
EP-3484878-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS Bristol-Myers Squibb Company (US) 2019-05-22 EP disclosed
WO-2000027394-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2000-05-18 WO disclosed
WO-2000009711-A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE α1/β1 (hsGCα1/β1) VASOPHARM BIOTECH GMBH & CO. KG (DE) 2000-02-24 WO disclosed
EP-0934311-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER AG (DE) 1999-08-11 EP disclosed
WO-1998016507-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1998-04-23 WO disclosed